Clinical Trial Search

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability

Primary: Safety (Reportable Adverse Events) — 1; 7; 2; 30 Participants

Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants

Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants

Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants

Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months

Primary: Increase of Interferon Gamma Levels — 0 Participants

Primary: The Safety of Administering DC Vaccines With Nivolumab — 0; 0 Percentage of patients

Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants

Primary: Overall Survival (OS) — 13.40; 14.88 Months — p=0.0037

Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC

Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants

Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants

Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…

Primary: Progression-free Survival at 6 Months — 23 Percentage of participants

Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel

Primary: Activity of Vemurafenib in Untreated Brain Metastases

Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants

Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants

Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants